Fig. 5
From: WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment
Effects of MK-1775 and talazoparib on MDS and AML cell proliferation. (A, B, C) MDS and AML cell lines were incubated with MK-1775 or talazoparib for 48 or 72 h. Cell growth (A), caspase 3/7 activity (B), and cytotoxicity (C) were evaluated. *p < 0.05 vs. the control. (D) MDS and AML cell lines were incubated with MK-1775 or talazoparib for 72 h. The MMP was analyzed by a Mitochondria Staining Kit. Significance was expressed as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns, not significant